Vizsgálati helyszín
Cape Town
Cape Town, Western 7800, Dél-afrikai KöztársaságMég nincs intézményhez kötve
- 16futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis21 vizsgálat
- 2. fázis2 vizsgálat
- 4. fázis2 vizsgálat
- Állapot
- Fut, nem toboroz11 vizsgálat
- Lezárult8 vizsgálat
- Toboroz5 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Novartis Pharmaceuticals25 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
NCT05776927· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
NCT05222529· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
CINC424A2X01B Rollover Protocol
NCT02386800· 4. fázis· Novartis Pharmaceuticals· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek